US does not approve AstraZeneca for chronic nasal disease

AstraZeneca said the US regulator has refused to approve the asthma drug Fasenra for the treatment of chronic rhinosinusitis with nasal polyps, a condition characterized by benign growths that cause pain and congestion.

Share this post:

Related Posts
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore
WordPress Cookie Plugin by Real Cookie Banner